

Figure S1. Kaplan-Meier estimates of the cumulative incidence of HPV-16 incident infection (A, D) and persistent infection (>6 months) (B, E) and persistent infection (>12 months) (C, F) among different HPV-16 serostatus groups. The log-rank test was used to analyse the differences among different serostatuses. HPV-16 Neu (-): seronegative for HPV-16 neutralizing antibodies; HPV-16 IgG (-): seronegative for HPV-16 IgG antibodies; HPV-16 IgG (+): seropositive for HPV-16 IgG antibodies.




Figure S2. Kaplan-Meier estimates of the cumulative incidence of HPV-18 incident infection (A, D) and persistent infection (>6 months) (B, E) and persistent infection (>12 months) (C, F) among different HPV-18 serostatus groups. The log-rank test was used to analyse the differences among different serostatuses. HPV-18 Neu (-): seronegative for HPV-18 neutralizing antibodies; HPV-18 IgG (-): seronegative for HPV-18 IgG antibodies; HPV-18 IgG (+): seropositive for HPV-18 IgG antibodies.